Ananda Health buys Elixinol U.S. operations and expands manufacturing platform

Ananda Health has acquired Elixinol’s U.S. operations and is broadening its contract manufacturing and 3PL business as federal hemp rules are set to change on Dec. 11, 2026. The move positions the Kentucky-based company to serve brands and pharmacies expected to face a smaller, more compliance-driven hemp market.

Why it matters: - Ananda Health is positioning itself to benefit from a likely shakeout in the hemp category when federal hemp law changes take effect Dec. 11, 2026. - The company is betting that brands with manufacturing, distribution and compliance infrastructure will gain share as weaker operators leave the market. - Independent pharmacies may become more important as consumers look for regulated alternatives and trained guidance.

What happened: - Ananda Health acquired Elixinol’s U.S. operations and added Elixinol to its brand platform. - Elixinol will continue as a standalone brand alongside Ananda Professional and Ananda Wellness. - Elixinol’s existing customers and product lines will keep being supported without interruption. - Ananda Health also expanded its contract manufacturing and third-party logistics offering for brand partners. - The company said it is developing new and reformulated products ahead of the federal hemp-law change.

The details: - Ananda Health is based in Georgetown, Kentucky, and describes itself as a vertically integrated manufacturer of dietary supplements and plant-derived wellness products. - The company’s facility is the only LEED Platinum dietary supplement facility in the United States. - The operation includes sourcing, formulation and R&D, cGMP manufacturing, quality and testing, and in-house pick, pack and ship. - Contract manufacturing covers white label, private label and toll manufacturing. - Current product formats include tinctures, topicals, molten/hot-fill products and gummies. - Powders and capsules are expected to be added soon. - The platform serves cannabinoid and non-cannabinoid products across the dietary supplement and wellness market. - Ananda Health currently serves more than 2,000 independent pharmacies nationwide. - The company’s products are available through independent pharmacies, AnandaProfessional.com, Elixinol.com and other e-commerce marketplaces. - The company also offers contract manufacturing and 3PL services to outside brands.

Between the lines: - The hemp market is headed into a narrower federal definition that could force many products to reformulate or exit the market. - The U.S. Hemp Roundtable estimates the proposed changes, if implemented as enacted, would eliminate roughly 95% of hemp products now on shelves. - The rule change would affect products with delta-8, delta-9, delta-10, THCA and HHC, many of which are sold in gas stations, vape shops and online. - Products that no longer meet the hemp definition would fall under the federal Controlled Substances Act. - Ananda Health says some existing products already comply, including GLP-1 Support Gummies, Stress Shots, Mobility Chews and Focus and Memory Chews. - The company is also launching reformulated replacement products designed to meet the revised definition. - The acquisition gives Ananda Health a larger base to sell both its own brands and manufacturing services to other companies navigating the transition.

What's next: - Ananda Health expects reformulation and product transitions to continue ahead of the Dec. 11, 2026 deadline. - The company plans to keep investing in Elixinol’s brand, product mix and customer experience. - Ananda Health said the independent pharmacy channel will remain central to its strategy. - The company is likely to keep pushing its U.S.-based manufacturing and fulfillment platform as brands look for compliant partners.

The bottom line: - Ananda Health is using a looming hemp rule change to scale up, buy a known brand and sell more manufacturing capacity at the same time.